… In this study, for the Japanese population dyspepsia was the most common AE during
treatment with dabigatran, which was same as in the overall study population. Dyspepsia, defined …

… In addition, previous real-world studies have compared the risk of major bleeding for NOACs
versus warfarin, the standard of care. Several real-world analysis comparing dabigatran to …

… to be confirmed in unselected patients in daily care. Objectives: To evaluate the efficacy,
safety and management issues of dabigatran anticoagulation in AF in daily care. Patients and …

… Methods We aimed to assess the consistency of efficacy and safety outcomes associated
with dabigatran etexilate (DE) versus warfarin in patients with AF in LA from the RE-LY (…

… is that dabigatran is safe among our population in clinical practice. The adverse effect
profile for dabigatran among our patients are lower than that in the RE-LY trial population. Our …

… , especially in older people. Evidence for bleeding risks … in real world setting is lacking.
Therefore we aimed to assess and compare real world bleeding risks with warfarin and dabigatran…

… safety of dabigatran in clinical practice setting and show the outcomes of a real world data. …
This study indicated that dabigatran appears to be non-inferior and safe drug for stroke …

… influence real-world performance of … dabigatran use are important to validate results from
the RE-LY trial. Overall, the available real-world data on the efficacy and safety of dabigatran in …

… populations, in the real world. Thus, the importance of observational studies in depicting ‘the
real world’ is … at 27,538 dabigatran-rivaroxaban patient pairs. This study which compared …

… data on the efficacy and safety of dabigatran, there may be differences … actual dabigatran
use at 4 adult hospitals, which together represent a variety of patient and prescriber populations…